Cherin P
Service de Médecine Interne, Hôpital de La Salpêtrière, 75651 Paris Cedex 13.
Ann Med Interne (Paris). 2000 May;151 Suppl 1:1S48-50.
Polymyositis and dermatomyositis are two inflammatory muscle diseases of unknown origin mediated by a dysimmune mechanism via a cytotoxic effect against the muscle fiber in polymyositis and a humoral effect against the muscle vessels in dermatomyositis. First line treatment of polymyositis and dermatomyositis is still based on corticosteroid therapy. In case of failure, corticosteroid dependence, or intolerance, a second line treatment using immunosuppressors or polyvalent human intravenous immunoglobulins (IVIg) is usually associated. We report our experience with IVIg in the treatment of 50 patients with myositis unresponsive to corticosteroids and immunosuppressors. Thirty-five patients had polymyositis and 15 had dermatomyositis. We discuss the possible mechanisms and their precise role in the therapeutic armamentarium in these dysimmune diseases.
多发性肌炎和皮肌炎是两种病因不明的炎症性肌肉疾病,由免疫失调机制介导,在多发性肌炎中通过对肌纤维的细胞毒性作用,在皮肌炎中通过对肌肉血管的体液作用。多发性肌炎和皮肌炎的一线治疗仍然基于皮质类固醇疗法。如果治疗失败、出现皮质类固醇依赖或不耐受情况,通常会联合使用免疫抑制剂或多价人静脉注射免疫球蛋白(IVIg)进行二线治疗。我们报告了我们使用IVIg治疗50例对皮质类固醇和免疫抑制剂无反应的肌炎患者的经验。35例患者患有多发性肌炎,15例患有皮肌炎。我们讨论了这些免疫失调疾病中可能机制及其在治疗手段中的精确作用。